A Phase l b/II a, Multicenter, Randomized, Double-Blinded, and Placebo-Controlled Study of the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C-Infection.
Phase of Trial: Phase I/II
Latest Information Update: 09 Oct 2012
At a glance
- Drugs Lomibuvir (Primary) ; Peginterferon; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 May 2012 Planned end date changed from 1 Jul 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History